期刊文献+

血液灌流对维持性血液透析患者微炎症状态的影响 被引量:2

Effects of Hemoperfusion on Micro- inflammation in Maintenance Hemodialysis Patients
原文传递
导出
摘要 目的:探讨血液透析联合血液灌流治疗对维持性血液透析患者微炎症状态及脂蛋白a的影响。方法选择我院血液净化中心维持性血液透析患者89例,随机分为治疗组( HD+HP组,男25例、女21例)和对照组( HD组,男23例、女20例)。另选择30名健康人作为正常组,监测治疗前后血清超敏C反应蛋白(hypersensitive C-reactive protein,hs-CRP)、白介素-6(interleukin-6,IL-6)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、脂蛋白a( lipoprotein-a,LP-a)的变化。结果 MHD患者普遍存在微炎症状态及LP-a代谢紊乱,与正常组对比,MHD患者hs-CRP、IL-6、TNF-α、LP-a等指标水平均显著升高( P﹤0.01);对照组血液透析治疗12周后hs-CRP、IL-6、TNF-α及LP-a水平较透析前升高( P﹤0.05);与对照组相比,治疗组血液灌流治疗12周后hs-CRP、IL-6、TNF-α等炎症因子水平明显降低( P﹤0.05),LP-a水平亦显著降低( P﹤0.05)。结论 MHD患者普遍存在微炎症状态及LP-a代谢紊乱;血液灌流治疗可减轻MHD患者微炎症状态及改善LP-a代谢紊乱。 Objective To investigate the effects of hemodialysis with hemoperfusion on micro -inflammatory state and Lipoprotein-a( LP-a). Methods 89 patients undergoing maintenance hemodialysis were randomly divid-ed into treatment group( HD+HP group,25 males and 21 females)and control group( HD group,23 males and 20 fe-males). 30 healthy adults were selected as healthy control group. Hypersensitive C-reactive protein( hs-CRP),in-terleukin-6(IL-6),tumor necrosis factor-α(TNF-α),lipoprotein-a(LP-a)were measured before and after treatment. Results Micro-inflammatory state and LP-a disorder were common in MHD group. Hs-CRP,IL-6, TNF-α and LP-a were significantly higher in MHD patients than those in healthy normal controls(P﹤0. 01). Hs-CRP,IL-6,TNF-α and LP-a were significantly higher in control group 12 weeks after hemodialysis(P﹤0. 05). Hs-CRP,IL-6,TNF-α and LP-a decreased significantly in treatment group than those in control group 12 weeks after hemodialysis(P﹤0. 05). Conclusion The micro-inflammatory status and disturbance of LP-a metabolism are common in MHD patients. Hemoperfusion can alleviate micro-inflammatory status and improve LP-a metabolic disorders.
出处 《医学新知》 CAS 2014年第4期241-244,共4页 New Medicine
关键词 血液灌流 血液透析 微炎症状态 脂蛋白A Hemoperfusion Hemodialysis Micro - inflammation Lipoprotein - a
  • 相关文献

参考文献15

  • 1Foley R N. Should hemoglobin be normalized in uremic patients[ J]. Clin Nephro1,2002,58 ( Suppll ) :58-61.
  • 2Chen S J,Jiang G R,shan J P,et al. Combination of maintenance he- modialysis with hemoperfusion : a safe and effective model of artificial kidney[J]. Int J Artif Organs,2011,34(4) :339-347.
  • 3Kalantar - Zadeh K T, Ikizler A T, Block G, et al. Malnutrition in-flammation complex syndrome in dialysis patients Causes and conse- quences [ J ]. Am J Kidney Dis, 2003,42 : 864-881.
  • 4Pennell P, Leelereq B, Dclahunty M I, et al. The utility of non - HDL in managing dyslipidemia of stage 5 chronic kidney disease[ J]. Clin Nephro1,2006,66(5 ) :336-347.
  • 5Ramirez R, Martin Malo A,Aljama P. Inflammation and hemodiafil- tration[ J]. Contrib Nephro1,2007 ,158 :210-215.
  • 6Beve S,Sabie S,Hoje R. Atherosclerosis in hemodialysis patients -the role of mieroinflammation[ J]. Ren Fail ,2008,30(10) : 1012-1016.
  • 7Boenisch O, Ehmke K D, Heddergott A, et al. C - reactive protein and cytokine plasma levels in hemodialysis patients [ J ]. J Nephrol, 2002,15(5) :547-551.
  • 8Tsirpanlis G, Chatzipanagiotou S, Nicolaou C. Mieroinflammation ver- sus inflammation in chronic renal failure patients [ J ]. Kidney Int, 2004,66:2093-2094.
  • 9Attman P O, Samuelsson O G, Moberly J, et al. Apolipoprotein B Containing Lipoproteins in renal failure : the relation to mode of dial- ysis [ J ]. Kidney Int, 1999,55 (4) : 1536-1542.
  • 10Diaz Peromingo J A ,Carbajal D G,Alban Salgado A. Lipoprotein(a) in patients on hemodialysis [ J]. Acta Med Austraca,2004,31 ( 3 ) 73 -75.

二级参考文献46

  • 1Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med, 2002,347(25):2010-2019.
  • 2Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol, 2002,13(5):1307-1320.
  • 3Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int, 2000,58:353-562.
  • 4Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med, 1999, 340(2): 115-126.
  • 5Memoli B, Postiglione L, Cianciaruso B, et al. Role of different dialysis membranes in the release of interleukin-6 soluble receptor in uremic patients. Kidney Int, 2000,58:417-424.
  • 6Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation, 2003, 107: 87-92.
  • 7Svensson M, Yu ZW, Eriksson JW. A small reduction in glomerular filtration is accompanied by insulin resistance in type 1 diabetes mellitus patients with diabetic nephropathy. Eur J Clin Invest, 2002,32:100-109.
  • 8Panichi V, Migliori M, De Pietro S, et al. C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron, 2002, 91(4): 594-600.
  • 9Pecoits-Filho R, Goncalves S, Barberato SH, et al. Impact of Residual Renal Function on Volume Status in Chronic Renal Failure. Blood Purif, 2004,22(3):285-292.
  • 10Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet, 1999,353(9167):1838-1842.

共引文献40

同被引文献12

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部